How could a new president impact the US's complex healthcare sector?

Possible pricing changes

William Ball, senior equity analyst at Sanlam Private Wealth, analyses the US's troubled healthcare system and the changes a new president could implement in the sector, which has been at the 'heart' of the election campaigns.

Drug pricing has certainly become an emotionally charged topic during the past few months. Healthcare stocks have broadly sold off since the end of July, in part down to investors rotating out of defensive equities. Hillary Clinton (pictured) condemned the "outrageous" and "price-gouging" practices of embattled manufacturer Mylan (which has hiked the price of its decade old anti-parasitic drug EpiPen by roughly 400% since 2008), and has called for an end to "unjustified price increases not for new innovations, but for long-available and generic treatments". Earlier this month, Clinton...